Population pharmacokinetics I: background, concepts, and models.
about
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatmentCovariate pharmacokinetic model building in oncology and its potential clinical relevance.Understanding and applying pharmacometric modelling and simulation in clinical practice and researchEstimation of pharmacokinetic parameters based on the patient-adjusted population data.Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo).Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunologyInterpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.Pharmacokinetics of recombinant activated factor VII in trauma patients with severe bleedingPopulation pharmacokinetics II: estimation methods.Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndromeFactors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients.Clinical trials in pediatric traumatic brain injury: unique challenges and potential responses.Manual blood exchange transfusion does not significantly contribute to parasite clearance in artesunate-treated individuals with imported severe Plasmodium falciparum malariaExternal evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimizationPopulation pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.Understanding the time course of pharmacological effect: a PKPD approach.Fundamentals of population pharmacokinetic modelling: modelling and software.Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Population pharmacokinetics of cyclosporine in transplant recipients.Population pharmacometrics in support of analgesics studies.Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow.Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections.Fundamentals of Population Pharmacokinetic Modelling : Modelling and Software.Pharmacokinetics and pharmacodynamics of dexmedetomidine.The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A.A Longitudinal HbA1c Model Elucidates Genes Linked to Disease Progression on Metformin.A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension.Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determination.Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response modelsChain length of dietary alkylresorcinols affects their in vivo elimination kinetics in rats.Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.
P2860
Q26862558-2F9663C9-9DDB-4F25-B82F-2427582B9BE0Q27687599-D5639644-084F-4214-A64A-ADA04D790D80Q28468334-95ECBDA9-7583-400E-B807-92F9B9C12C71Q31082856-F5C803B9-F1C2-4C7F-9490-E8245BA03696Q31147438-88E9E84C-35D3-4AC1-B0F2-C300813EEB37Q33571417-8E4F5760-1935-4FB9-A212-03A7EAF55886Q33827819-10CB91DF-1F99-44CB-BF07-0D0ED9E7D4A3Q34996894-FEAE5286-26D4-42C3-B5E6-5465D1E4EF3CQ35544621-8DC12B06-EAE6-40E4-8F4D-8A80AF854324Q35887615-38840D64-1AF5-4B46-9936-45C4F287E117Q35928858-AF75C975-9BF7-46EB-99D3-93B5388A8CEFQ35972218-D0560500-D737-4F73-8E59-C350389E570EQ36545066-9628F729-262C-449F-A1E2-E0B86DAC44E1Q36582084-80D497A0-F01C-4BE9-833B-3DBEED440C81Q36741273-6982A3CD-B83B-4D5A-BB98-63208EBB2632Q36806621-673379F6-C38C-43AB-99D6-D84877F0BF58Q37237006-9AB8FAC2-8358-45F5-B357-BA719993F764Q37298637-F7B0F105-4194-4943-AB2B-64DA8C0E7FEFQ37298794-0A1B7E13-BA5D-49BE-9B76-DC4BDF37711EQ37832754-D18A0615-C88C-4E0B-81CA-D37859FFCE64Q38016955-B7A05FE5-8B52-41F3-9CAA-B2B77CF9696DQ38103885-7E827DD5-8C21-4B48-B8F2-F601F9AFC94BQ38115174-580E21B7-465F-49D5-A1DA-6D315BC04968Q38175171-D1F0F0EF-B799-498D-AF7F-D2E31FBCA062Q38233301-41D6CDE6-2207-4DD1-87DD-36790166A540Q38258649-AFC74C58-5B1C-4326-AAD8-4451F44AF821Q38930366-7D554746-F91D-4EA4-86F0-4BFE60E91A10Q38946488-89A161E2-2FEE-454E-A53D-1F2D5FA107B8Q39475869-496D2522-245A-4EA8-B77D-0E408B21DEFEQ39602527-E7E8FECE-206A-4546-BBDD-476FC5929A6AQ39816357-1C017AE2-EFF5-4DA7-A90B-C08560E9CFEDQ39956407-69CBC098-B760-482D-AEA5-46FE05A5368AQ40749709-BED94328-6454-4C97-A7F1-18EE4B5810DEQ41819996-7A742E38-A266-4C4B-BDD6-CCB732CA11DBQ42218978-9C376E40-C3B2-4097-AFDB-B7B6567EB828Q43451894-D71A52E2-980F-43A2-B710-E5B93D9C8286Q43984406-AAD45BC9-B8BF-4A19-8FFB-96B5D1C95197Q44796146-FE256534-8522-440A-8D67-22106964EF7FQ45869569-F64EBF76-C8A6-4B43-86DB-F5405234FB05Q46244052-30000269-A1EE-418F-A96F-5E59E6DA0984
P2860
Population pharmacokinetics I: background, concepts, and models.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Population pharmacokinetics I: background, concepts, and models.
@ast
Population pharmacokinetics I: background, concepts, and models.
@en
type
label
Population pharmacokinetics I: background, concepts, and models.
@ast
Population pharmacokinetics I: background, concepts, and models.
@en
prefLabel
Population pharmacokinetics I: background, concepts, and models.
@ast
Population pharmacokinetics I: background, concepts, and models.
@en
P2860
P356
P1476
Population pharmacokinetics I: background, concepts, and models.
@en
P2093
Ene I Ette
Paul J Williams
P2860
P304
P356
10.1345/APH.1D374
P407
P577
2004-08-24T00:00:00Z